Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Establishing Reference Ranges of Hematological Parameters from Malian Healthy Adults.

Kone B, Maiga M, Baya B, Sarro Y, Coulibaly N, Kone A, Diarra B, Sanogo M, Togo A, Goita D, Dembele M, Polis MA, Warfield J, Belson M, Dao S, Orsega S, Murphy RL, Diallo S, Siddiqui S.

J Blood Lymph. 2017;7(1). pii: 154. doi: 10.4172/2165-7831.1000154. Epub 2017 Mar 15.

2.

Clinical characteristics of non-tuberculous mycobacterial pulmonary infections in Bamako, Mali.

Kone B, Sarro YS, Maiga M, Sanogo M, Somboro AM, Diarra B, Togo ACG, Coulibaly N, Dembele BPP, Goita D, Baya B, Kone A, Diabaté S, Polis MA, Belson M, Dao S, Orsega S, Achenbach CJ, Murphy RL, Diallo S, Siddiqui S.

Epidemiol Infect. 2018 Feb;146(3):354-358. doi: 10.1017/S0950268817003090. Epub 2018 Jan 15.

3.

Performance of microscopic observation drug susceptibility for the rapid diagnosis of tuberculosis and detection of drug resistance in Bamako, Mali.

Sanogo M, Kone B, Diarra B, Maiga M, Baya B, Somboro AM, Sarro YS, Togo ACG, Dembele BPP, Goita D, Kone A, M'Baye O, Coulibaly N, Diabate S, Traore B, Diallo MH, Coulibaly YI, Saleeb P, Belson M, Orsega S, Siddiqui S, Polis MA, Dao S, Murphy RL, Diallo S.

Clin Microbiol Infect. 2017 Jun;23(6):408.e1-408.e6. doi: 10.1016/j.cmi.2017.01.004. Epub 2017 Jan 18.

4.

Tuberculosis drug resistance in Bamako, Mali, from 2006 to 2014.

Diarra B, Goita D, Tounkara S, Sanogo M, Baya B, Togo AC, Maiga M, Sarro YS, Kone A, Kone B, M'Baye O, Coulibaly N, Kassambara H, Cisse A, Belson M, Polis MA, Otu J, Gehre F, Antonio M, Dao S, Siddiqui S, Murphy RL, de Jong BC, Diallo S.

BMC Infect Dis. 2016 Nov 28;16(1):714.

5.

Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.

Rosenthal ES, Kottilil S, Polis MA.

Expert Opin Pharmacother. 2016;17(5):743-9. doi: 10.1517/14656566.2016.1157580. Epub 2016 Mar 16. Review.

6.

Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo.

Simonetti FR, Sobolewski MD, Fyne E, Shao W, Spindler J, Hattori J, Anderson EM, Watters SA, Hill S, Wu X, Wells D, Su L, Luke BT, Halvas EK, Besson G, Penrose KJ, Yang Z, Kwan RW, Van Waes C, Uldrick T, Citrin DE, Kovacs J, Polis MA, Rehm CA, Gorelick R, Piatak M, Keele BF, Kearney MF, Coffin JM, Hughes SH, Mellors JW, Maldarelli F.

Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1883-8. doi: 10.1073/pnas.1522675113. Epub 2016 Feb 8.

7.

Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir.

Townsend K, Petersen T, Gordon LA, Kohli A, Nelson A, Seamon C, Gross C, Tang L, Osinusi A, Polis MA, Masur H, Kottilil S.

AIDS. 2016 Jan;30(2):261-6. doi: 10.1097/QAD.0000000000000903.

PMID:
26691547
8.

High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study.

Petersen T, Townsend K, Gordon LA, Sidharthan S, Silk R, Nelson A, Gross C, Calderón M, Proschan M, Osinusi A, Polis MA, Masur H, Kottilil S, Kohli A.

Hepatol Int. 2016 Mar;10(2):310-9. doi: 10.1007/s12072-015-9680-7. Epub 2015 Nov 26.

9.

Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.

Kohli A, Kattakuzhy S, Sidharthan S, Nelson A, McLaughlin M, Seamon C, Wilson E, Meissner EG, Sims Z, Silk R, Gross C, Akoth E, Tang L, Price A, Jolley TA, Emmanuel B, Proschan M, Teferi G, Chavez J, Abbott S, Osinusi A, Mo H, Polis MA, Masur H, Kottilil S.

Ann Intern Med. 2015 Dec 15;163(12):899-907. doi: 10.7326/M15-0642. Epub 2015 Nov 24.

PMID:
26595450
10.

Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease.

Kattakuzhy S, Wilson E, Sidharthan S, Sims Z, McLaughlin M, Price A, Silk R, Gross C, Akoth E, McManus M, Emmanuel B, Shrivastava S, Tang L, Nelson A, Teferi G, Chavez J, Lam B, Mo H, Osinusi A, Polis MA, Masur H, Kohli A, Kottilil S.

Clin Infect Dis. 2016 Feb 15;62(4):440-447. doi: 10.1093/cid/civ897. Epub 2015 Oct 26.

11.

International Collaborative Research Partnerships: Blending Science with Management and Diplomacy.

Lau CY, Wang C, Orsega S, Tramont EC, Koita O, Polis MA, Siddiqui S.

J AIDS Clin Res. 2014 Dec;5(12). pii: 385.

12.

Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.

Kohli A, Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B, Silk R, Kotb C, Gross C, Teferi G, Sugarman K, Pang PS, Osinusi A, Polis MA, Rustgi V, Masur H, Kottilil S.

Lancet Infect Dis. 2015 Sep;15(9):1049-1054. doi: 10.1016/S1473-3099(15)00157-7. Epub 2015 Jul 14.

13.
14.

Treatment of hepatitis C virus infection.

Kottilil S, Wright M, Polis MA, Masur H.

Ann Intern Med. 2015 Mar 17;162(6):459. doi: 10.7326/L15-5064-4. No abstract available.

PMID:
25775329
15.

Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.

Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, Bon D, Silk R, Gross C, Price A, Sajadi M, Sidharthan S, Sims Z, Herrmann E, Hogan J, Teferi G, Talwani R, Proschan M, Jenkins V, Kleiner DE, Wood BJ, Subramanian GM, Pang PS, McHutchison JG, Polis MA, Fauci AS, Masur H, Kottilil S.

JAMA. 2015 Mar 24-31;313(12):1232-9. doi: 10.1001/jama.2015.1373.

PMID:
25706232
16.

Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.

Kohli A, Osinusi A, Sims Z, Nelson A, Meissner EG, Barrett LL, Bon D, Marti MM, Silk R, Kotb C, Gross C, Jolley TA, Sidharthan S, Petersen T, Townsend K, Egerson D, Kapoor R, Spurlin E, Sneller M, Proschan M, Herrmann E, Kwan R, Teferi G, Talwani R, Diaz G, Kleiner DE, Wood BJ, Chavez J, Abbott S, Symonds WT, Subramanian GM, Pang PS, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S.

Lancet. 2015 Mar 21;385(9973):1107-13. doi: 10.1016/S0140-6736(14)61228-9. Epub 2015 Jan 13.

17.

HCC surveillance results in earlier HCC detection: results from an Indian cohort.

Kohli A, Murphy AA, Agarwal C, Shivakumar B, Kottilil S, Polis MA, Subramanian GM, Midha V, Goyal O, Desai S, Sood A, Shah S.

Springerplus. 2014 Oct 17;3:610. doi: 10.1186/2193-1801-3-610. eCollection 2014.

18.

Treatment of hepatitis C virus infection: is it time for the internist to take the reins?

Kottilil S, Wright M, Polis MA, Masur H.

Ann Intern Med. 2014 Sep 16;161(6):443-4. doi: 10.7326/M14-0741. No abstract available.

PMID:
25222390
19.

Short communication: serum-based assay accurately detects single nucleotide polymorphisms of IL28B and SOCS3 in HIV/hepatitis C virus-coinfected subjects.

Shaffer A, Hubbard JJ, Townsend K, Kottilil S, Polis MA, Masur H, Kohli A.

AIDS Res Hum Retroviruses. 2014 Aug;30(8):792-5. doi: 10.1089/AID.2014.0028. Epub 2014 Jul 14.

20.

Inteleukin-23 promotes interferon-α responsiveness in hepatitis C virus/HIV-coinfected patients.

Odigie M, Osinusi A, Barrett L, Townsend K, Wang H, Suffredini AF, Masur H, Polis MA, Kottilil S.

AIDS Res Hum Retroviruses. 2014 Aug;30(8):775-82. doi: 10.1089/AID.2014.0003. Epub 2014 Jun 30.

21.

Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.

Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, Sneller M, Kohli A, Barrett L, Proschan M, Herrmann E, Shivakumar B, Gu W, Kwan R, Teferi G, Talwani R, Silk R, Kotb C, Wroblewski S, Fishbein D, Dewar R, Highbarger H, Zhang X, Kleiner D, Wood BJ, Chavez J, Symonds WT, Subramanian M, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S.

JAMA. 2013 Aug 28;310(8):804-11. doi: 10.1001/jama.2013.109309. Erratum in: JAMA. 2013 Nov 13;310(18):1987. Dosage error in article text.

22.

Baseline CD4+ T-cell counts predict HBV viral kinetics to adefovir treatment in lamivudine-resistant HBV-infected patients with or without HIV infection.

Cortez KJ, Proschan MA, Barrett L, Brust DG, Weatherley B, Formentini E, Davey RT, Masur H, Polis MA, Neumann And AU, Kottilil S.

HIV Clin Trials. 2013 Jul-Aug;14(4):149-59. doi: 10.1310/hct1404-149.

23.

Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients.

Funk EK, Shaffer A, Shivakumar B, Sneller M, Polis MA, Masur H, Heytens L, Nelson A, Kwan R, Kottilil S, Kohli A.

AIDS Res Hum Retroviruses. 2013 Sep;29(9):1190-4. doi: 10.1089/AID.2013.0035. Epub 2013 Jun 14.

24.

HIV populations are large and accumulate high genetic diversity in a nonlinear fashion.

Maldarelli F, Kearney M, Palmer S, Stephens R, Mican J, Polis MA, Davey RT, Kovacs J, Shao W, Rock-Kress D, Metcalf JA, Rehm C, Greer SE, Lucey DL, Danley K, Alter H, Mellors JW, Coffin JM.

J Virol. 2013 Sep;87(18):10313-23. doi: 10.1128/JVI.01225-12. Epub 2013 May 15.

25.

Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients.

Kushner LE, Wendelboe AM, Lazzeroni LC, Chary A, Winters MA, Osinusi A, Kottilil S, Polis MA, Holodniy M.

PLoS One. 2013 Apr 4;8(4):e60387. doi: 10.1371/journal.pone.0060387. Print 2013.

26.

ACP Journal Club: a clinical decision-support system with interactive alerts improved CD4 cell count in HIV.

Polis MA.

Ann Intern Med. 2013 Apr 16;158(8):JC11. doi: 10.7326/0003-4819-158-8-201304160-02011. No abstract available.

PMID:
23588764
27.

ACP Journal Club. Preexposure prophylaxis reduced HIV-1 spread in serodiscordant heterosexual couples.

Polis MA.

Ann Intern Med. 2012 Nov 20;157(10):JC5-3. doi: 10.7326/0003-4819-157-10-201211200-02003. No abstract available.

PMID:
23165679
28.

IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin.

Osinusi A, Chary A, Winters MA, Naggie S, Masur H, Polis MA, Kottilil S, Holodniy M.

J Med Virol. 2012 Oct;84(10):1522-7. doi: 10.1002/jmv.23376.

29.

Failure to recognize nontuberculous mycobacteria leads to misdiagnosis of chronic pulmonary tuberculosis.

Maiga M, Siddiqui S, Diallo S, Diarra B, Traoré B, Shea YR, Zelazny AM, Dembele BP, Goita D, Kassambara H, Hammond AS, Polis MA, Tounkara A.

PLoS One. 2012;7(5):e36902. doi: 10.1371/journal.pone.0036902. Epub 2012 May 16.

30.

Molecular strain typing of Mycobacterium tuberculosis complex in Bamako, Mali.

Traore B, Diarra B, Dembele BP, Somboro AM, Hammond AS, Siddiqui S, Maiga M, Kone B, Sarro YS, Washington J, Parta M, Coulibaly N, M'baye O, Diallo S, Koita O, Tounkara A, Polis MA.

Int J Tuberc Lung Dis. 2012 Jul;16(7):911-6. doi: 10.5588/ijtld.11.0397. Epub 2012 Apr 9.

PMID:
22508197
31.

Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.

Naggie S, Osinusi A, Katsounas A, Lempicki R, Herrmann E, Thompson AJ, Clark PJ, Patel K, Muir AJ, McHutchison JG, Schlaak JF, Trippler M, Shivakumar B, Masur H, Polis MA, Kottilil S.

Hepatology. 2012 Aug;56(2):444-54. doi: 10.1002/hep.25647. Epub 2012 Jul 2.

32.

ACP Journal Club. Early antiretroviral therapy reduced HIV-1 transmission in serodiscordant couples.

Polis MA.

Ann Intern Med. 2011 Dec 20;155(12):JC6-8. doi: 10.7326/0003-4819-155-12-201112200-02008. No abstract available.

PMID:
22184709
33.

HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients.

Sidique N, Kohli A, Shivakumar B, Migueles S, Subramanian GM, Naggie S, Polis MA, Masur H, Kottilil S.

J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):e38-40. doi: 10.1097/QAI.0b013e31822d463f. No abstract available.

34.

Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy.

Murphy AA, Herrmann E, Osinusi AO, Wu L, Sachau W, Lempicki RA, Yang J, Chung TL, Wood BJ, Haagmans BL, Kottilil S, Polis MA.

AIDS. 2011 Jun 1;25(9):1179-87. doi: 10.1097/QAD.0b013e3283471d53. Erratum in: AIDS. 2011 Nov 13;25(17):2195. Chung, Tei L [corrected to Chung, Tje L].

35.

HCV in peripheral blood mononuclear cells are predominantly carried on the surface of cells in HIV/HCV co-infected individuals.

Natarajan V, Kottilil S, Hazen A, Adelsberger J, Murphy AA, Polis MA, Kovacs JA.

J Med Virol. 2010 Dec;82(12):2032-7. doi: 10.1002/jmv.21906.

PMID:
20981790
36.

Proteome-wide anti-hepatitis C virus (HCV) and anti-HIV antibody profiling for predicting and monitoring the response to HCV therapy in HIV-coinfected patients.

Burbelo PD, Kovacs JA, Ching KH, Issa AT, Iadarola MJ, Murphy AA, Schlaak JF, Masur H, Polis MA, Kottilil S.

J Infect Dis. 2010 Sep 15;202(6):894-8. doi: 10.1086/655780.

37.

Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients.

Chary A, Winters MA, Kottilil S, Murphy AA, Polis MA, Holodniy M.

J Infect Dis. 2010 Sep 15;202(6):889-93. doi: 10.1086/655784.

38.

Interferon-alpha produces significant decreases in HIV load.

Tavel JA, Huang CY, Shen J, Metcalf JA, Dewar R, Shah A, Vasudevachari MB, Follmann DA, Herpin B, Davey RT, Polis MA, Kovacs J, Masur H, Lane HC.

J Interferon Cytokine Res. 2010 Jul;30(7):461-4. doi: 10.1089/jir.2009.0090.

39.

Mycobacterium tuberculosis Beijing strain, Bamako, Mali.

Diarra B, Siddiqui S, Sogoba D, Traore B, Maiga M, Washington J, Tounkara A, Polis MA.

Emerg Infect Dis. 2010 Feb;16(2):362-3. doi: 10.3201/eid1602.090501. No abstract available.

40.

HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do.

Osinusi A, Rasimas JJ, Bishop R, Proschan M, McLaughlin M, Murphy A, Cortez KJ, Polis MA, Masur H, Rosenstein D, Kottilil S.

J Acquir Immune Defic Syndr. 2010 Mar;53(3):357-63. doi: 10.1097/QAI.0b013e3181c7a29d.

41.

Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics.

Rozenberg L, Haagmans BL, Neumann AU, Chen G, McLaughlin M, Levy-Drummer RS, Masur H, Dewar RL, Ferenci P, Silva M, Viola MS, Polis MA, Kottilil S.

AIDS. 2009 Nov 27;23(18):2439-50. doi: 10.1097/QAD.0b013e32832ff1c0.

42.

Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts.

Avidan NU, Goldstein D, Rozenberg L, McLaughlin M, Ferenci P, Masur H, Buti M, Fauci AS, Polis MA, Kottilil S.

J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):452-8. doi: 10.1097/QAI.0b013e3181be7249.

43.

Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to mapatumumab-induced apoptosis.

Zhang X, Frank AC, Gille CM, Daucher M, Kabat J, Becker S, Lempicki RA, Cortez KJ, Polis MA, Subramanian GM, Kottilil S.

Hepatol Res. 2009 Dec;39(12):1178-89. doi: 10.1111/j.1872-034X.2009.00568.x. Epub 2009 Sep 25.

PMID:
19788693
44.

Association of interleukin-15-induced peripheral immune activation with hepatic stellate cell activation in persons coinfected with hepatitis C virus and HIV.

Allison RD, Katsounas A, Koziol DE, Kleiner DE, Alter HJ, Lempicki RA, Wood B, Yang J, Fullmer B, Cortez KJ, Polis MA, Kottilil S.

J Infect Dis. 2009 Aug 15;200(4):619-23. doi: 10.1086/600107.

45.

Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells.

Kottilil S, Yan MY, Reitano KN, Zhang X, Lempicki R, Roby G, Daucher M, Yang J, Cortez KJ, Ghany M, Polis MA, Fauci AS.

Hepatology. 2009 Jul;50(1):34-45. doi: 10.1002/hep.23055.

46.

Identification and characterization of CRF02_AG, CRF06_cpx, and CRF09_cpx recombinant subtypes in Mali, West Africa.

Imamichi H, Koita O, Dabitao D, Dao S, Ibrah M, Sogoba D, Dewar RL, Berg SC, Jiang MK, Parta M, Washington JA, Polis MA, Lane HC, Tounkara A.

AIDS Res Hum Retroviruses. 2009 Jan;25(1):45-55. doi: 10.1089/aid.2008.0111.

47.

Identification of novel markers for liver fibrosis in HIV/hepatitis C virus coinfected individuals using genomics-based approach.

Suzman DL, McLaughlin M, Hu Z, Kleiner DE, Wood B, Lempicki RA, Mican JM, Suffredini A, Masur H, Polis MA, Kottilil S.

AIDS. 2008 Jul 31;22(12):1433-9. doi: 10.1097/QAD.0b013e328304dfe7.

48.

Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors.

Zonios DI, Falloon J, Bennett JE, Shaw PA, Chaitt D, Baseler MW, Adelsberger JW, Metcalf JA, Polis MA, Kovacs SB, Kovacs JA, Davey RT, Lane HC, Masur H, Sereti I.

Blood. 2008 Jul 15;112(2):287-94. doi: 10.1182/blood-2007-12-127878. Epub 2008 May 2. Erratum in: Blood. 2014 Jul 17;124(3):463. Kovacs, Stephen J [corrected to Kovacs, Stephen B].

49.

Multidrug-resistant and extensively drug-resistant tuberculosis: the National Institute of Allergy and Infectious Diseases Research agenda and recommendations for priority research.

Fauci AS; NIAID Tuberculosis Working Group.

J Infect Dis. 2008 Jun 1;197(11):1493-8. doi: 10.1086/587904. Review. No abstract available.

PMID:
18426366
50.

Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase.

Kearney M, Palmer S, Maldarelli F, Shao W, Polis MA, Mican J, Rock-Kress D, Margolick JB, Coffin JM, Mellors JW.

AIDS. 2008 Feb 19;22(4):497-501. doi: 10.1097/QAD.0b013e3282f29478.

Supplemental Content

Loading ...
Support Center